AnaptysBio is a clinical-stage antibody development company advancing therapeutic antibody product candidates focused on unmet medical needs in inflammation.

AnaptysBio, Inc. 10770 Wateridge Circle Suite 210 San Diego, CA 92121-5801 . Phone: (858) 362-6295 info@anaptysbio.com

AnaptysBio, Inc. 10770 Wateridge Circle Suite 210 San Diego, CA 92121-5801 (858) 362-6295 (ph) info@anaptysbio.com

Rosnilimab is a novel PD-1 agonist that reduces overactive T cell inflammation. It has two distinct mechanisms of action, depletion and agonism, prevalent both in inflamed tissue and the periphery, targeting PD-1+ T cells broadly impacting multiple drivers of disease pathogenesis

Immune cell modulators are a novel therapeutic class with the potential to deliver differentiated outcomes in autoimmune and inflammatory diseases including dermatology, gastroenterology, and rheumatology

Imsidolimab is an IgG4 antibody that inhibits the function of the interleukin-36 receptor (IL-36R), a signaling pathway within the immune system shown to be involved in the pathogenesis of inflammatory diseases, including GPP

We never conduct our interview process via messaging apps, freelance sites or social media platforms (i.e., Google Hangouts, WhatsApp, Signal, etc.). We only communicate with potential candidates through an official Anaptys email address ending in “@anaptysbio.com.”

All authors are current or previous employees of AnaptysBio, Inc. • First-in-human, double-blind, randomized, placebo‐controlled single ascending dose (SAD) and multiple ascending dose (MAD) study of ANB032 in healthy subjects.

AnaptysBio, Inc. 10770 Wateridge Circle Suite 210 San Diego, CA 92121-5801 . Phone: (858) 362-6295 info@anaptysbio.com

Jun 30, 2024 · SAN DIEGO, Aug. 05, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported financial results for the second quarter ended June 30, 2024 and provided a business update.